Mincyclin reduces secondary nerve degeneration
Back to overview
Numerous preclinical studies have shown that the compound minocycline had a neuroprotective effect, reducing the extent of progressive tissue loss.
The University of Calgary initiated a “randomized controlled clinical trial” (RCT) treating patients with acute spinal cord injury and started recruiting patients in 2004.
More information here